Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 13/20 | 0.72 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490044 | 1.00 | SOS1 (0.72) | SOS1NPY5RABCG2EGFRSLC2A1 | |
| SCHEMBL22342965 | 0.85 | SOS1 (0.79) | SOS1NPY5RABCG2EGFRSLC2A1 | |
| SCHEMBL20564785 | 0.84 | SOS1 (0.57) | SOS1 | |
| SCHEMBL29490030 | 0.84 | SOS1 (0.57) | SOS1 | |
| SCHEMBL29490075 | 0.83 | SOS1 (1.00) | SOS1NPY5RABCG2EGFR | |
| SCHEMBL22321839 | 0.83 | SOS1 (1.00) | SOS1NPY5RABCG2EGFR | |
| SCHEMBL29490107 | 0.83 | SOS1 (0.52) | SOS1NPY5RSLC2A1MEN1KMT2A | |
| SCHEMBL22321777 | 0.83 | SOS1 (0.52) | SOS1NPY5RSLC2A1MEN1KMT2A | |
| SCHEMBL22321870 | 0.82 | SOS1 (0.76) | SOS1 | |
| SCHEMBL29490038 | 0.82 | SOS1 (0.76) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | VANDERBILT UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | NRAS, KRAS, MAVS | SOS1 353/4885NPY5R 4278/4885ABCG2 2853/4885 |
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | NRAS, KRAS, MAVS | SOS1 353/4885NPY5R 4278/4885ABCG2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.